<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216333</url>
  </required_header>
  <id_info>
    <org_study_id>IUATLD CT Study C</org_study_id>
    <nct_id>NCT00216333</nct_id>
  </id_info>
  <brief_title>Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis</brief_title>
  <official_title>International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Union Against Tuberculosis and Lung Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>International Union Against Tuberculosis and Lung Diseases</source>
  <brief_summary>
    <textblock>
      The use of fixed-dose combined (FDC) drugs in the treatment of tuberculosis by National
      Tuberculosis Programmes has been recommended by both the International Union Against
      Tuberculosis and Lung Disease (The Union) and the World Health Organisation. The advantages
      of FDC drugs include preventing the emergence of drug resistance due to monotherapy, reducing
      the risk of incorrect dosage, simplifying procurement and prescribing practices, aiding
      adherence and facilitating directly observed treatment. Recent bioavailability studies of
      four-drug FDC tablets have demonstrated satisfactory results. In this study, we are testing
      the efficacy of this compound, when given in the initial intensive phase of treatment of
      patients with newly diagnosed smear positive pulmonary tuberculosis. This will be followed by
      four months treatment with a two-drug FDC of rifampicin and isoniazid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multiple country, multicenter study, using the parallel group open-label randomised
      trial design. The primary objective of this investigation is to assess the efficacy,
      acceptability and toxicity of a combined FDC regimen of chemotherapy in patients with newly
      diagnosed smear positive pulmonary tuberculosis in comparison with the standard regimen using
      separate drugs.

      Patients will be allocated at random either :

        -  an initial intensive phase of eight weeks of daily ethambutol, isoniazid, rifampicin and
           pyrazinamide, in a fixed dose COMBINED tablet, followed by 18 weeks of rifampicin and
           isoniazid, in a fixed dose combined tablet three times a week (2COMB/4(RH)3) or

        -  the same drugs given in SEPARATE formulations in the initial intensive phase of eight
           weeks, followed by 18 weeks of rifampicin and isoniazid, in a fixed dose combined
           tablet, three times a week (2SEPA/4(RH)3)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2003</start_date>
  <completion_date>June 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy : combined rate of failure at the end of treatment and relapse by 30 months.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety : occurrence of serious adverse events at any time during chemotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum culture results at two months of chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of completion of chemotherapy according to the protocol</measure>
  </secondary_outcome>
  <enrollment>1500</enrollment>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combined fixed dose combination</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed pulmonary tuberculosis

          -  two sputum specimens positive for acid-fast bacilli on direct smear microscopy

          -  no previous anti-tuberculosis chemotherapy

          -  aged 18 years and over

          -  firm home address that is readily accessible for visiting for the duration of the
             trial (including follow up period)

          -  agree to participate in the study and to give a sample of blood for HIV test

        Exclusion Criteria:

          -  patients in a moribund state,

          -  TB meningitis,

          -  pre-existing diseases: insulin-dependent diabetes, liver or kidney disease, blood
             disorders, peripheral neuritis,

          -  pregnancy or breast feeding,

          -  psychiatric illness

          -  alcoholism

          -  contraindication to any medications in the study regimens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Lienhardt, MD</last_name>
    <role>Study Director</role>
    <affiliation>International Union Against Tuberculosis and Lung Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharlette Cook, MPH</last_name>
    <phone>+33 1 44 32 06 47</phone>
    <email>scook@iuatld.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Lienhardt, MD</last_name>
    <phone>+ 33 1 44 32 06 43</phone>
    <phone_ext>06 43</phone_ext>
    <email>clienhardt@iuatld.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Pneumo-phtisiologie de Matiben</name>
      <address>
        <city>Algiers</city>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noureddine Zidouni, MD</last_name>
      <phone>213-21 93 13 86</phone>
      <email>nzidouni@sante.dz</email>
    </contact>
    <investigator>
      <last_name>Noureddine Zidouni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Program Nal. de Control de la Tuberculosis</name>
      <address>
        <city>Santa Cruz</city>
        <country>Bolivia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirtha Camacho, MD</last_name>
      <phone>59122211275</phone>
      <email>tbcos@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Segondo Guzman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Internacional de Entrenamiento</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Juan Francisco Miranda, MD</last_name>
      <phone>57 2 668 2164</phone>
      <email>mirandaf@cideim.org.co</email>
    </contact>
    <investigator>
      <last_name>Gustavo Montero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ignace Deen</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamadou D BARRY, MD</last_name>
      <phone>224 29 86 40</phone>
      <email>mdtelibarry@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Boubacar BAH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Resesarch Center of Manhica</name>
      <address>
        <city>Manhica</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mateu Dr Mateu Espasa, MD</last_name>
      <phone>+ 258 1 81 01 81</phone>
      <email>mateu.espasa@manhica.net</email>
    </contact>
    <investigator>
      <last_name>Mateu Espasa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nepal Anti-Tuberculosis Association</name>
      <address>
        <city>Kathmandu</city>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grupo Levir S.A.</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Víctor Manuel Chávez Pérez, MD</last_name>
      <phone>+51-1-328-2451</phone>
      <email>chzpz@viabcp.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Ticona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute for Medical Research</name>
      <address>
        <city>Mwanza</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital of TB and Respiratory Diseases</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sy Dinh Ngoc, MD, PhD</last_name>
      <phone>0913284158</phone>
      <email>vnntp463@hn.vnn.vn</email>
    </contact>
    <investigator>
      <last_name>Thuy Ha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Bolivia</country>
    <country>Colombia</country>
    <country>Guinea</country>
    <country>Mozambique</country>
    <country>Nepal</country>
    <country>Peru</country>
    <country>Tanzania</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 12, 2006</last_update_submitted>
  <last_update_submitted_qc>September 12, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2006</last_update_posted>
  <keyword>tuberculosis</keyword>
  <keyword>fixed dose combination</keyword>
  <keyword>DOT</keyword>
  <keyword>shot-course chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

